I n this issue of Circulation Research, Sossalla et al 1 show that acute inhibition of Ca 2ϩ /calmodulin-dependent protein kinase (CaMK)II in failing human myocardium causes functional improvement in contractility by restoring a positive force-frequency relationship (FFR) in cardiac trabeculae. The loss of this normal positive FFR (and often an induction of a negative FFR) is a functional hallmark of failing human myocardium 2 and has been seen as an intrinsic limitation of the failing heart to enhance contractility appropriately at higher heart rates. This failure of positive FFR also constitutes a reduction in functional cardiac reserve. So, why might CaMKII inhibition be beneficial in heart failure (HF)?
CaMKII Activity in Heart Failure and Functional Molecular Targets
For several years, evidence has been accumulating that CaMKII is increased in both expression level and activity in both animal models of HF and in failing human hearts. [3] [4] [5] [6] [7] [8] [9] It has also come to light that CaMKII has many different functional effects in cardiac myocytes, including alterations in ion channels, Ca 2ϩ handling proteins, myofilaments, and transcriptional regulation. 10 -12 Moreover, many of these CaMKII effects on myocyte properties have been implicated in hypertrophy, HF, and arrhythmias in animal models. Indeed, CaMKII inhibition (or knockout of the dominant cardiac isoform CaMKII␦) can improve cardiac function and delay the onset of maladaptive aspects of the hypertrophic/HF phenotype in animal models, resulting in beneficial functional effects. [13] [14] [15] Sossalla et al 1 provide important novel data that acute CaMKII inhibition in human HF myocardium causes functional improvement. This is an important validation step with respect to consideration of cardiac CaMKII inhibition as therapeutic strategy in human HF. So, what are some key acute functional effects of CaMKII that can alter cardiac Ca 2ϩ handling and excitability? CaMKII phosphorylates Thr17 on phospholamban (PLN), which can relieve the inhibitory effect of PLN on the sarcoplasmic reticulum (SR) Ca-ATPase and thereby enhance Ca 2ϩ uptake into the SR. This PLN effect of CaMKII would be positively inotropic and lusitropic (like PKA-dependent phosphorylation at Ser16 on PLN). These PLN effects could enhance arrhythmogenic events indirectly by enhancing SR Ca 2ϩ content (and enhancing diastolic SR Ca 2ϩ release), but that is not the point here. Moreover, blocking this inotropic effect of CaMKII would be in the wrong direction for the observed effects.
The SR Ca 2ϩ release channel (ryanodine receptor [RyR]) associates with and is phosphorylated by CaMKII at Ser2814 (and possibly Ser2808). 10 This phosphorylation has generally been found to activate both diastolic SR Ca 2ϩ leak (sometimes visualized as Ca 2ϩ sparks) and sensitize the RyR to Ca 2ϩ -induced Ca 2ϩ release during excitation-contraction coupling. When this CaMKII effect is strong, as in transgenic mice overexpressing CaMKII␦ C (the predominant cardiac cytosolic isoform) and in HF models, it can cause dramatic reduction in SR Ca 2ϩ content available for release. This can result in strong depression of contractility, even though CaMKII enhances the fractional SR Ca 2ϩ release during excitation-contraction coupling. 5, 16, 17 This seems to be the key pathway involved in the human HF studies of Sossalla et al, 1 where CaMKII inhibition improved contractility at higher heart rates by reducing SR Ca 2ϩ leak and enhancing SR Ca 2ϩ content.
CaMKII also mediates Ca 2ϩ -dependent facilitation of Ca 2ϩ current (I Ca ) in cardiac myocytes, whereby I Ca amplitude is increased and inactivation is slowed by repetitive depolarization or at higher heart rates. I Ca facilitation would tend to increase both Ca 2ϩ influx and SR Ca 2ϩ content, and thus inhibition would be in the opposite direction to explain the beneficial effects of CaMKII inhibition. On the other hand, the slow [Ca 2ϩ ] i decline seen in HF would tend to slow recovery of I Ca from inactivation (especially at high heart rates), 18, 19 because of direct effects of Ca 2ϩ /calmodulindependent inactivation (independent of CaMKII). Therefore, I Ca reduction might contribute to the more negative FFR in HF. However, in this case, CaMKII inhibition could only enhance I Ca by reducing late diastolic [Ca] i , which could again be mediated by reduced diastolic SR Ca 2ϩ leak via RyR. In addition, enhanced SR Ca 2ϩ uptake could also reduce diastolic [Ca] i , but CaMKII inhibition neither accelerated twitch relaxation rate nor altered PLN phosphorylation in HF in the present study.
CaMKII also causes complex effects on Na ϩ current (I Na ) gating, 20 above). However, this would also tend to reduce SR Ca content, which is not what was observed. CaMKII also influences potassium currents in ways that can shorten action potential duration. In that setting, CaMKII inhibition could prolong action potential duration and enhance Ca 2ϩ loading of the myocyte and SR. The bottom line is that the beneficial effect of CaMKII inhibition on contractility and Ca 2ϩ transients in human HF myocytes 1 could include a complicated mix of multiple effects on the above pathways. However, it is quite plausible that the RyR effects are the most important factor, and their measurements of Ca 2ϩ sparks and SR Ca 2ϩ load are consistent with this interpretation.
There is general agreement that in HF CaMKII␦ is upregulated and is also more autophosphorylated (which leads to autonomous CaMKII activity even after [Ca 2ϩ ] i declines and calmodulin dissociates from the kinase). CaMKII can also reach this autonomous activation state by oxidation of 2 methionine residues in the same regulatory domain of CaMKII. 22 However, the detailed mechanism is not yet known for either the upregulation or activation of CaMKII in HF. In addition, the phosphorylation level of each CaMKII target is the net result of kinase and phosphatase action. In HF, there is an increase in myocyte phosphatase activity, although it seems to be lost from the local RyR complex. 5, 23 The enhanced global phosphatase activity in HF might explain why Sossalla et al 1 did not see reduction in PLN or L-type Ca 2ϩ channel subunit phosphorylation with CaMKII inhibition (they might have been kept low in HF by the high global phosphatase activity). However, the loss of RyRassociated phosphatase in HF may allow the more active CaMKII bound there to more fully phosphorylate the RyR (and cause enhanced SR Ca 2ϩ leak) that is reversed by CaMKII block.
We previously showed in a rabbit HF model that acute CaMKII inhibition could reduce diastolic SR Ca 2ϩ leak, enhance SR Ca 2ϩ load, and significantly increase twitch Ca 2ϩ transient amplitude. 5 However, the systolic Ca 2ϩ transient restoration was modest, falling short of the control heart level (despite essentially full restoration of SR Ca 2ϩ load). We reasoned that the benefit of the enhanced SR Ca 2ϩ load with CaMKII inhibition was significantly limited by the loss of a normal CaMKII-dependent enhancement of fractional SR Ca 2ϩ release for a given I Ca trigger and SR Ca 2ϩ load. 17 It is possible that the balance of these 2 facets of RyR effects of CaMKII differs in the failing human heart here (eg, versus that rabbit HF model). On the other hand, it is not clear whether SR Ca 2ϩ load experiments here were performed in conditions that allow this sort of quantitative analysis. It is also unclear how well the CaMKII inhibition restores function versus nonfailing human tissue, because nonfailing samples were not available for comparison (although the FFR with KN-93 was comparable to prior work from this group with nonfailing human trabeculae 2 ). In any event, the functional improvement in the human HF muscles here is quite substantial at higher heart rates, making this an exciting result with CaMKII inhibition, even if the mechanistic explanation is incompletely resolved.
FFR in Human and Animal Myocardium
Human nonfailing myocardium exhibits a robust positive FFR, and this is true for rabbit, guinea pig, dog, and most other larger mammals. Extensive work over the past 50 years has provided the major explanations for this phenomenon. 24 The increase in frequency provides greater Ca 2ϩ influx (via I Ca ) per unit time and there is less diastolic time between beats for Ca 2ϩ extrusion to occur, resulting in increased cellular and SR Ca 2ϩ load. In addition, there is greater influx of Na ϩ per unit time both because of more frequent I Na , but also because of more Na ϩ entry via Na ϩ /Ca 2ϩ exchange (driven by the higher Ca influx), This limits the ability of Na ϩ /Ca 2ϩ exchange to extrude Ca 2ϩ during the shortened diastolic interval, again adding to the cellular and SR Ca 2ϩ gain. This mechanism has been confirmed by measuring SR Ca 2ϩ load, which rises in parallel with the FFR. If SR Ca 2ϩ is already near maximum, little further Ca 2ϩ loading occurs with increasing frequency, and the FFR is typically flat or negative. A negative inotropic effect of increase frequency is an accumulation of refractoriness of the RyR to activation by I Ca (and perhaps reduced I Ca availability at higher frequencies). If SR Ca 2ϩ load fails to increase substantially with frequency, this negative effect can dominate to yield a flat or even negative FFR. This negative effect of increased frequency also occurs in normal human or rabbit myocytes, but it is usually masked by the even stronger positive effects of SR Ca 2ϩ loading. It may well be that the inability of the leaky SR in HF to strongly increase SR Ca 2ϩ load at higher frequency allows the negative effect to become more dominant in HF. Inhibition of that CaMKII-induced leak would then allow higher SR Ca 2ϩ load to be achieved and restoration of the positive FFR.
A cautionary note here is that rat and mouse ventricular myocytes tend to have flat or negative (and only sometimes slightly positive) FFR and little or no gain in SR Ca 2ϩ load with increasing frequency. This is probably because rat and mouse myocytes exhibit much higher physiological [Na ϩ ] i , which limits diastolic Ca 2ϩ extrusion and keeps the SR nearly at capacity even during rest. 24 My personal opinion is that both I Ca facilitation, and this CaMKII-dependent enhancement of fractional SR Ca 2ϩ release (that we first described in 1997 17 ) are, at most minor, contributors to the physiological FFR. Moreover, a larger fractional SR Ca 2ϩ release will gradually unload the SR to a new steady state, where a larger fraction of a smaller SR Ca 2ϩ load is released, resulting in little change in the steady-state systolic Ca 2ϩ transient (as shown elegantly by Eisner et al 25 ) . In a pathophysiological state like HF, strong CaMKIIdependent RyR phosphorylation can elevate diastolic SR Ca 2ϩ leak so strongly that SR Ca 2ϩ load is dramatically reduced, effectively creating a limiting SR Ca 2ϩ load and preventing frequency-dependent increases in SR Ca 2ϩ load. More work is clearly needed, but it seems that cardiac CaMKII inhibition in human HF might be of some functional benefit.
Sources of Funding
Supported by NIH grants P01-HL080101 and R37-HL30077.
Disclosures
None.
